FindMyKOL
Clinical trialNCT05645380Active, not recruitingPhase 2Interventional

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

SponsorUniversity of Kansas Medical CenterEnrollment139Breast CancerTriple Negative Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • the University of Kansas Cancer Center - Clinical Research Center

    Fairway, Kansas, United States

  • the University of Kansas Cancer Center - Main Hospital

    Kansas City, Kansas, United States

  • the University of Kansas Cancer Center - Westwood

    Kansas City, Kansas, United States

  • the University of Kansas Cancer Center - Overland Park

    Overland Park, Kansas, United States

  • the University of Kansas Cancer Center - North

    Kansas City, Missouri, United States

  • the University of Kansas Cancer Center - Lee'S Summit

    Lee's Summit, Missouri, United States

  • University of Kansas Cancer Center at North Kansas City Hospital

    North Kansas City, Missouri, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Cyclophosphamide →Docetaxel →Doxorubicin →Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
5 Dec 2022
Primary completion
31 Dec 2026
Completion
31 Dec 2028
Last update posted
28 Apr 2026
Registered enrollment
139
Registry id
NCT05645380
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.